The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec or Mencevax ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

Final Report: A Phase IIIb, Open, Multi-Center Study to Evaluate the Long-Term Antibody Persistence at 6, 7, 8p, 9, and 10 Years After the Administration of One Dose of the Meningococcal Conjugate Vaccine MenACWY-TT Versus One Dose of Meningitec® Vaccine or One Dose of the Meningococcal Polysaccharide Vaccine Mencevax ACWY, and to Evaluate the Safety and Immunogenicity of a Booster Dose of MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination of 1-10 Year Old Subjects With MenACWY-TT, Meningitec, or Mencevax ACWY

Category & Conditions:
Vaccine-related Conditions
Medicine:
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C0921004
Open Plain Language Summary Result:Click here